Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
RASP modulation platform described as a drug-delivery/platform technology.
|
$334.82M |
$5.59
+6.27%
|
|
PYXS
Pyxis Oncology, Inc.
MICVO employs a drug-delivery platform approach (extracellular matrix targeting with a cleavable linker and cytotoxic payload).
|
$327.46M |
$5.29
-1.03%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$322.64M |
$6.46
+2.70%
|
|
SLN
Silence Therapeutics plc
Platform-based drug delivery (GalNAc-siRNA) enabling targeted delivery for siRNA therapies.
|
$322.63M |
$6.88
+8.35%
|
|
LRMR
Larimar Therapeutics, Inc.
The CPP-based delivery platform is a core technology used to deliver nomlabofusp, i.e., Drug Delivery Platforms.
|
$302.13M |
$3.53
-3.81%
|
|
NGNE
Neurogene Inc.
EXACT is a proprietary platform technology for drug delivery/regulation of transgene expression in gene therapy.
|
$299.57M |
$20.84
+0.48%
|
|
SCPH
scPharmaceuticals Inc.
Drug Delivery Platforms is a core technology enabling the subcutaneous administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
TARA
Protara Therapeutics, Inc.
IV Choline Chloride is described as a platform for phospholipid substrate replacement, i.e., a Drug Delivery Platform.
|
$285.70M |
$7.41
-1.98%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$282.72M |
$5.21
-2.62%
|
|
CADL
Candel Therapeutics, Inc.
enLIGHTEN HSV-based platform represents a drug delivery platform used to design and optimize viral immunotherapies.
|
$253.62M |
$4.62
+3.47%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$249.07M |
$12.97
+0.12%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Drug delivery platforms tag fits the proprietary plant virus nanoparticle delivery technology used to modulate immune responses.
|
$240.84M |
$0.60
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$237.27M |
$5.20
+13.04%
|
|
VYGR
Voyager Therapeutics, Inc.
ALPL-based non-viral shuttle and TRACER capsids represent a Drug Delivery Platforms technology.
|
$223.54M |
$4.04
+1.76%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$221.93M |
$6.21
+1.31%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's nasal spray represents a drug delivery platform/format for self-administration.
|
$221.84M |
$2.61
+5.67%
|
|
EDIT
Editas Medicine, Inc.
Drug Delivery Platforms: proprietary delivery platform (tLNP) enabling in vivo gene editing.
|
$215.81M |
$2.40
+0.21%
|
|
GNLX
Genelux Corporation
CHOICE is a platform-based drug delivery approach for immunotherapies, fitting Drug Delivery Platforms.
|
$211.15M |
$5.59
+5.77%
|
|
PEPG
PepGen Inc.
The Enhanced Delivery Oligonucleotide (EDO) platform represents a drug delivery technology, justifying the Drug Delivery Platforms tag.
|
$199.75M |
$6.08
+0.50%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$185.31M |
$3.46
+29.59%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Core technology platforms STARR sa-mRNA and LUNAR delivery system enabling RNA therapeutics.
|
$184.65M |
$6.79
-0.15%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA utilizes an intranasal delivery method for Foralumab, representing a Drug Delivery Platforms approach.
|
$184.53M |
$1.80
-1.10%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$171.69M |
$1.11
+1.83%
|
|
CATX
Perspective Therapeutics, Inc.
Developing a drug-delivery platform around the 212Pb radiopharmaceuticals and regional finishing capabilities.
|
$165.61M |
$2.25
+2.51%
|
|
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Proprietary drug delivery platform enabling brain tumor targeting and BBB bypass; platform used for delivery of therapeutics.
|
$164.29M |
$8.71
-1.47%
|
|
THTX
Theratechnologies Inc.
SORT1+ Technology platform functions as a drug-delivery platform enabling peptide-drug conjugates.
|
$155.87M |
$3.39
|
|
ELTX
Elicio Therapeutics, Inc.
AMP platform described as a drug delivery platform targeting lymph nodes.
|
$149.66M |
$9.15
+2.23%
|
|
MCRB
Seres Therapeutics, Inc.
MbTx Platform is Seres' core drug-delivery platform enabling the design and cultivation of targeted live biotherapeutic consortia.
|
$147.69M |
$16.93
+0.03%
|
|
SGMO
Sangamo Therapeutics, Inc.
STAC-BBB represents a CNS drug-delivery platform enabling systemic delivery across the blood-brain barrier.
|
$140.02M |
$0.46
+10.84%
|
|
VTGN
VistaGen Therapeutics, Inc.
Pherine platform represents a non-systemic intranasal drug-delivery approach developed by the company.
|
$139.29M |
$4.56
-2.77%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 employs a sustained-release drug-delivery platform for intravesical administration.
|
$139.07M |
$4.18
-1.88%
|
|
MRSN
Mersana Therapeutics, Inc.
Dolasynthen and Immunosynthen platforms are drug delivery platforms enabling targeted ADC payload delivery.
|
$137.44M |
$27.63
+0.82%
|
|
ALEC
Alector, Inc.
Alector Brain Carrier (ABC) is a proprietary drug delivery platform to enhance brain exposure and enable subcutaneous administration.
|
$136.64M |
$1.34
+5.08%
|
|
MOLN
Molecular Partners AG
DARPin platform represents a drug-delivery/modular platform enabling targeted biologics.
|
$136.10M |
N/A
|
|
CYBN
Cybin Inc.
CYB004 utilizes a deuterated drug delivery approach including an inhalation platform, indicating a Drug Delivery Platforms capability.
|
$120.61M |
$6.04
-2.11%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$116.86M |
$2.87
-0.52%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$116.43M |
$1.64
+1.86%
|
|
IKT
Inhibikase Therapeutics, Inc.
Prodrug technology used in IKT-001Pro represents a drug-delivery platform approach.
|
$114.76M |
$1.54
-1.59%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$113.35M |
$39.40
-2.45%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$108.68M |
$2.48
-0.40%
|
|
INO
Inovio Pharmaceuticals, Inc.
CELLECTRA delivery technology represents a drug delivery platform enabling in vivo DNA plasmid delivery.
|
$104.16M |
$1.97
+8.56%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$101.40M |
$10.12
+7.14%
|
|
ACOG
Alpha Cognition Inc. Common Stock
The company references sublingual and coated tablet formulations, indicating a drug delivery platform focus.
|
$98.42M |
$6.08
-0.33%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell and TVGN platform described as a drug delivery platform enabling cell therapies.
|
$94.62M |
$0.49
+10.94%
|
|
ADAG
Adagene Inc.
Drug Delivery Platforms capturing the platform-based approach to activating antibodies in tumors.
|
$93.85M |
$2.12
+6.53%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK represents a drug-delivery platform concept (off-the-shelf cell therapy) enabling administration of therapy.
|
$87.44M |
$3.59
+6.53%
|
|
ADVM
Adverum Biotechnologies, Inc.
The program relies on a proprietary drug delivery platform (vector-based) for sustained expression of a therapeutic protein.
|
$87.29M |
$4.17
+1.83%
|
|
VXRT
Vaxart, Inc.
The VAAST platform constitutes a Drug Delivery Platform enabling oral, needle-free vaccines with mucosal immunity and room-temperature stability.
|
$81.83M |
$0.36
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$80.57M |
$1.36
+3.41%
|
|
STRO
Sutro Biopharma, Inc.
XpressCF+/ADC platform constitutes a drug delivery platform used to create and optimize ADCs.
|
$75.14M |
$0.89
+3.53%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX2004 leverages a proprietary linker-payload platform, aligning with the Drug Delivery Platforms category.
|
$73.90M |
$1.39
-4.48%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan's PharmFilm technology and related drug-delivery approaches indicate a Drug Delivery Platforms capability.
|
$69.59M |
$0.72
+1.16%
|
|
SIGY
Sigyn Therapeutics, Inc.
ChemoPrep/ChemoPure platforms imply drug-delivery optimization via extracorporeal circuits, fitting Drug Delivery Platforms.
|
$68.37M |
$1.40
|
|
BMEA
Biomea Fusion, Inc.
Platform technology (FUSION System) used to discover/develop covalent small molecule drugs, representing a drug discovery platform.
|
$63.67M |
$1.06
+3.40%
|
|
VRCA
Verrica Pharmaceuticals Inc.
YCANTH uses a proprietary drug-device combination applicator, aligning with a drug delivery platform.
|
$63.38M |
$6.76
+32.03%
|
|
OSTX
OS Therapies Incorporated
Drug Delivery Platforms tag captures the tunable linker/ delivery platform used in OST-tADC.
|
$59.00M |
$1.81
+0.56%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$54.10M |
$4.89
+2.19%
|
|
BCAB
BioAtla, Inc.
CAB platform is a conditional antibody/drug delivery platform used to activate drug in tumor microenvironment.
|
$49.95M |
$0.85
+2.93%
|
|
CUE
Cue Biopharma, Inc.
Immuno-STAT represents a drug delivery platform for targeted, injectable biologics.
|
$48.09M |
$0.66
+8.23%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
ARC/Radiopharmaceutical platform represents a drug delivery platform enabling targeted radiotherapy.
|
$45.23M |
$1.46
+4.29%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$44.82M |
$2.03
+2.53%
|
|
HOWL
Werewolf Therapeutics, Inc.
PREDATOR platform represents a drug delivery platform enabling tumor-selective activation.
|
$44.68M |
$0.98
+7.67%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$44.39M |
$3.20
|
|
JUNS
Jupiter Neurosciences, Inc.
Drug Delivery Platforms: JOTROL is a proprietary micellar delivery system improving bioavailability.
|
$42.15M |
$1.22
+3.39%
|
|
ATHE
Alterity Therapeutics Limited
Alterity's iron chaperone platform represents a drug-delivery/platform technology that redistributes iron to modulate disease pathways.
|
$40.22M |
N/A
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$40.08M |
$4.01
+2.69%
|
|
OTLC
Oncotelic Therapeutics, Inc.
Nanoparticle-based delivery platform for six anticancer agents constitutes a Drug Delivery Platform.
|
$38.90M |
$0.09
|
|
XLO
Xilio Therapeutics, Inc.
Drug Delivery Platforms reflects Xilio's tumor-activation masking technology designed to localize activity within tumors.
|
$38.88M |
$0.75
-0.25%
|
|
APLT
Applied Therapeutics, Inc.
ARI platform represents a drug-delivery/targeting platform aiming for tissue-specific penetration, a defined drug-delivery platform category.
|
$38.05M |
$0.27
+6.38%
|
|
NXTC
NextCure, Inc.
NextCure’s ADC technology represents a drug delivery platform that enables targeted payload delivery to tumors.
|
$36.48M |
$13.89
-0.43%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 employs a dry powder inhalation delivery approach, representing a Drug Delivery Platforms category.
|
$35.89M |
$1.55
+6.51%
|
|
GBIO
Generation Bio Co.
ctLNP is a proprietary drug delivery platform enabling targeted, redosable delivery of nucleic acids.
|
$35.70M |
$5.34
+1.71%
|
|
GNTA
Genenta Science S.p.A.
Temferon uses a drug-delivery platform to express payloads in the tumor microenvironment.
|
$35.48M |
$1.95
+1.56%
|
|
MURA
Mural Oncology plc
Engineered cytokine platform underlying the programs represents a Drug Delivery Platform/therapeutic delivery approach.
|
$35.00M |
$2.02
-3.57%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$34.86M |
$0.71
+3.77%
|
|
BTAI
BioXcel Therapeutics, Inc.
Sublingual film formulation BXCL501 represents a drug-delivery platform; included as Drug Delivery Platforms.
|
$30.28M |
$2.10
+9.69%
|
|
PASG
Passage Bio, Inc.
PBFT02 leverages a drug delivery platform (AAV1/ICM) to deliver progranulin to the CNS.
|
$28.58M |
$8.65
-3.65%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$28.53M |
$0.68
+9.26%
|
|
TLPH
Talphera, Inc.
The company emphasizes drug delivery platform concepts through lyophilized nafamostat formulations and IV/compounded administration approaches.
|
$26.88M |
$1.31
-0.38%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$24.40M |
$1.85
+4.52%
|
|
IBIO
iBio, Inc.
ShieldTx and related antibody engineering imply a Drug Delivery Platform approach to spatially control activity.
|
$23.59M |
$1.21
+2.99%
|
|
AKTX
Akari Therapeutics, Plc
Drug delivery platforms conceptually underpin the novel ADC payloads and linker technologies.
|
$22.08M |
$0.46
+3.45%
|
|
AYTU
Aytu BioPharma, Inc.
The company employs a Time Release Resin Particle (TRRP) proprietary technology, aligning with the 'Drug Delivery Platforms' category.
|
$20.82M |
$2.13
+0.71%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 employs a gut-restricted prodrug delivery approach, representing a Drug Delivery Platforms technology.
|
$20.34M |
$2.22
+3.26%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$19.67M |
$1.12
+3.70%
|
|
SYBX
Synlogic, Inc.
Synlogic positions its Synthetic Biotics as a Drug Delivery Platform enabling localized GI therapy.
|
$19.30M |
$1.69
+1.20%
|
|
COSM
Cosmos Health Inc.
Uses nanoemulsification technology to enhance absorption (e.g., Melatonin Spray), representing a Drug Delivery Platforms capability.
|
$19.14M |
$0.63
+0.70%
|
|
INTS
Intensity Therapeutics, Inc.
DfuseRx platform and INT230-6.00 involve a drug-delivery platform enabling intratumoral delivery and systemic immune effects.
|
$18.65M |
$0.40
+1.34%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$18.23M |
$3.77
+2.45%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide functions as a drug-delivery platform to enhance tumor penetration and co-administered therapies.
|
$17.95M |
$2.06
-0.24%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$17.77M |
$3.33
+1.83%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$16.89M |
$10.86
+0.51%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$16.40M |
$4.54
+5.21%
|
|
HOTH
Hoth Therapeutics, Inc.
BioLexa platform and HT-001 formulation imply a drug delivery platform approach (localized/topical delivery).
|
$15.91M |
$1.21
+3.42%
|
|
NXGL
NEXGEL, Inc.
NXGEL's hydrogel platform enables drug delivery and controlled release applications.
|
$14.68M |
$1.84
+2.50%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$13.82M |
$0.41
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
Veripure represents a drug-delivery platform for pharmaceutical-grade RBS and PV-10 formulations.
|
$13.68M |
$0.07
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
FHAB constitutes a proprietary drug delivery platform intended to extend half-life and improve tumor targeting of biologics.
|
$13.15M |
$4.16
-0.12%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$12.50M |
$1.62
+12.50%
|
|
THAR
Tharimmune, Inc.
TH023 leverages external oral-delivery platforms (Soteria/Phloral) via Intract, representing a Drug Delivery Platform technology.
|
$11.87M |
$2.58
+2.79%
|
Showing page 2 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
